Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects.

@article{Farid2009EffectOR,
  title={Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects.},
  author={Nagy A. Farid and Joseph A. Jakubowski and Christopher D. Payne and Ying Li and Yu Ho Jin and C S Ernest and Kenneth J. Winters and John Brandt and Daniel E. Salazar and David S. Small},
  journal={Current medical research and opinion},
  year={2009},
  volume={25 8},
  pages={1821-9}
}
OBJECTIVE Prasugrel is a thienopyridine antiplatelet agent for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Since cytochrome P450 enzymes CYP3A4 and CYP2B6 play a major role in prasugrel's active metabolite formation, the effect of potent CYP induction by rifampin on the… CONTINUE READING